MK0557
DrugMK0557 10mg tablet qd for a 15-wk treatment period
NCT Number: NCT00482430
The purpose of this study is to determine the safety and effectiveness of an investigational drug for the treatment of cognitive impairment in patients with schizophrenia.
Looking for future studies?
Notify Me21 year–55 year
All sexes
Interventional
Phase 2
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
MK0557 10mg tablet qd for a 15-wk treatment period
MK0557 Pbo tablet qd for a 15-wk treatment period
Time frame: at 4 weeks of treatment
Time frame: at 4 weeks of treatment
Merck Sharp & Dohme LLC
Industry
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04902066
Behavior, Behavioral Symptoms
Copenhagen, Hellerup, Denmark
View Trial DetailsNCT00506077
Mental Disorders, Paranoid Schizophrenia
View Trial DetailsNCT06007105
Acute and Transient Psychotic Disorder, Bipolar Type I Disorder With Psychotic Symptoms
Blantyre, Southern Region, Malawi
View Trial DetailsNCT04324944
Delusional Disorder, Major Depressive Disorder With Psychotic Features
San Diego, California, United States
View Trial Details